Skip to Content

Umeclidinium Bromide



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Muscarinic receptor antagonist (anticholinergic, parasympatholytic agent)

Treatment of COPD (chronic obstructive pulmonary disease)

Chemical Name

1-{2-[(benzyl)oxy]etyl}4-[hydroxydi(phenyl)metyl]-1-azabicyclo[2.2.2]octan-1-ium bromide (WHO)

Foreign Names

  • Umeclidinium bromdium (Latin)
  • Umeclidinium bromid (German)
  • Um├ęclidinium, bromure d' (French)
  • Umeclidinio, bromuro de (Spanish)

Generic Names

  • Umeclidinium Bromide (OS: USAN)
  • GSK573719A (IS)
  • UNII-7AN603V4JV (IS)
  • Umeclidinium bromide (PH: JP XVI)

Brand Names

  • Anoro (Umeclidinium Bromide and Vilanterol)
    Glaxo Group, Austria; Glaxo Group, Cyprus; Glaxo Group, Poland; Glaxo Operations UK, Macedonia; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Chile; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Finland; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Sweden; GlaxoSmithKline, Slovakia; GlaxoSmithKline, United States; GSK, Belgium; Wellcome Limited, Bosnia & Herzegowina
  • Anoro Ellipta (Umeclidinium Bromide and Vilanterol)
    GlaxoSmithKline, Canada; GlaxoSmithKline, United States; GlaxoSmithKline UK, United Kingdom
  • Incruse
    Glaxo Group, Poland; Glaxo GRP, United States; GlaxoSmithKline, Germany; GlaxoSmithKline, Finland; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Sweden; GlaxoSmithKline Laboratoire Pharmaceutique, France; GlaxoSmithKline UK, United Kingdom
  • Incruse Ellipta
    GlaxoSmithKline, Switzerland
  • Laventair (Umeclidinium Bromide and Vilanterol)
    Glaxo Group, Poland


ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.